Connected datasets provide a 360° view of the patient
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Citeline, a Norstella company and leading provider of clinical, drug and commercial intelligence for the life sciences industry, introduces Patient Intelligence, providing a complete view of the patient to help teams make patient-first decisions across clinical trial feasibility and protocol planning.
Patient Intelligence unites robust patient data with the trusted trial, site and pipeline intelligence of Cite line’s Trialtrove, Sitetrove and Pharmaprojects. These datasets feed workflows across the Citeline platform, including trial design, site selection and patient recruitment planning.
Patient Intelligence is comprised of:
- Patient Population: Global epidemiology data combines with country-level mapping to reveal whether there is a sizable patient population for a given disease and where it is located.
- Standard of Care: A live view of the treatment landscape for a given disease, starting with oncology using guideline-recommended regimens by biomarker, therapy line and region, helps clients deepen their understanding of the patient standard of care recommendations.
- Patient Journey: Drawing on the depth of de-identified real-world data (RWD) within NorstellaLinQ, this approach brings together open claims, electronic health records (EHR) and clinical notes and social determinants of health (SDOH) to create a more complete view of the patient. By connecting clinical signals across the patient journey, from diagnosis and treatment decisions to line-of-therapy progression and transitions in care, it captures the clinical nuance and context often missed by individual data sources alone, enabling more precise protocol-to-patient targeting.
- Patient Access and Proximity: Built into Sitetrove and mapped to investigator and site records, this capability uses open claims and SDOH data from NorstellaLinQ to pinpoint sites and investigators with access to relevant and diverse patient populations across the US and 19 additional countries, and identifies US physicians near those investigators who have access to the right patients for referral.
Together, these datasets also help connect patients to providers and sites, for optimized patient recruitment. In addition, based on the selected indication, Patient Intelligence pulls in relevant advocacy groups and enables sponsors to network with them for possible recruitment.
“Every successful clinical trial starts with a patient,” says Madeline Naylor, Citeline Chief Clinical Officer. “Patient Intelligence brings the patient layer into Citeline's AI-ready foundation of pipeline, trial and site data, all in one trusted source of truth.
“We're not just helping sponsors understand pipelines, trials, sites and investigators in isolation, we're helping them to connect those decisions back to the patient,” she says. “Patient Intelligence helps teams bring patient reality into the decisions that shape a trial from the very beginning.”
To learn more about Patient Intelligence, visit Citeline.com.
About Citeline
Citeline, backed by the strength of Norstella, the AI company for biopharma's highest-stakes decisions, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical-, commercial- and regulatory-related decisions and create real-world opportunities for growth.
Citeline’s global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering them all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X.
Media Contact
Norstella@DiffusionPR.com
(213) 318-4500
-
KLB科洛百获26年度科学配方大奖,以制药标准重塑ECM抗衰体系,开启细胞级修护新纪元在2026第三届中国化妆品科学开品大会上,2026年度BSFA科学配方大奖正式揭晓,KLB科洛百千日菊肌源紧致精华液(时光棒)凭借创新ECM细胞外基质调控配方、扎实2026-09-11
-
2026服贸会 | 中医药转化应用项目集中落地,九体医学核心成果独家转让北京百灵谷图说 / 北京中医药大学科技园管理办公室、技术转移转化中心主任张礼财与北京百灵谷中医医学研究院院长刘平签约 中医药的生命力在于传承,更在于转化应用。2026-09-11
-
Starlight Investments宣布成功关闭英国BTR基金II随着Starlight继续巩固其在英国最大的BTR运营商中的地位,第二期基金和辅助投资工具的资本承诺总额为6.8亿英镑,将支持6,000多套住房的收购和交付 多伦多2026年9月12026-09-11
-
2026深圳“十佳主播”选树活动启动,寻找镜头内外的“圳能量”一方屏幕,连接千行百业;一次开播,记录城市脉动。在深圳,越来越多网络主播用镜头讲述城市故事,以专业助力品牌成长,更把善意送到需要的地方。每一次真诚表达、每一份责2026-09-10
-
CordenPharma 扩充无菌灌装与封装产能,无菌注射剂年产能将达 5 亿支CordenPharma 将在数年内投资 8,000 万欧元,新增生产设施及无菌灌装与封装生产线,加快扩充无菌注射剂 CDMO 产能 瑞士巴塞尔2026年9月10日 美通社 -- CordenPharma2026-09-10
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
-
2026 雷瓦亮相京东 MALL ,匠心筑造专业造型新标杆
